Franklin Biotechnology Discovery Fund Class C FBTDX

Medalist Rating as of | See Franklin Templeton Investment Hub
  • NAV / 1-Day Return 160.99  /  −0.40 %
  • Total Assets 1.1B
  • Adj. Expense Ratio
    1.760%
  • Expense Ratio 1.760%
  • Distribution Fee Level Below Average
  • Share Class Type Level Load
  • Category Health
  • Investment Style Mid Growth
  • Min. Initial Investment 1,000
  • Status Open
  • TTM Yield 1.46%
  • Turnover 38%

USD | NAV as of Oct 03, 2026 | 1-Day Return as of Oct 03, 2026, 12:11 AM GMT+0

Morningstar’s Analysis FBTDX

Will FBTDX outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

Still not a standout despite a hot streak.

Associate Analyst Natalia Arrigoni

Natalia Arrigoni

Associate Analyst

Summary

Franklin Biotechnology Discovery’s veteran managers and strong recent results inspire some confidence, but limited research support and an undifferentiated process limit its appeal.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings FBTDX

  • Current Portfolio Date
  • Equity Holdings —
  • Bond Holdings —
  • Other Holdings —
  • % Assets in Top 10 Holdings 36.6
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Jazz Pharmaceuticals PLC

5.06 62M
Healthcare

Amgen Inc

4.65 57M
Healthcare

argenx SE ADR

4.15 51M
Healthcare

Gilead Sciences Inc

4.11 50M
Healthcare

Vertex Pharmaceuticals Inc

3.83 47M
Healthcare

Regeneron Pharmaceuticals Inc

3.74 46M
Healthcare

Revolution Medicines Inc Ordinary Shares

3.13 38M
Healthcare

AstraZeneca PLC

2.72 33M
Healthcare

Ascendis Pharma AS

2.68 33M
Healthcare

Amylyx Pharmaceuticals Inc

2.57 31M
Healthcare

Sponsor Center